The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Coding Corner Answer: August Coding Challenge

Coding Corner Answer: August Coding Challenge

August 8, 2012 • By Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Take the challenge…

You Might Also Like
  • Coding Corner Answer: July Coding Challenge
  • Coding Corner Answer: December Coding Challenge
  • Coding Corner Answer
Explore This Issue
August 2012
Also By This Author
  • Rheumatology Professionals and Patient Advocates Take Their Stories to Capitol Hill

Answer: 99213-25, 96413, 96415 x 1, 96375, J1200 x1, J1745 x20

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Diagnosis: 714.0

This infusion procedure is billed with a level-three evaluation and management (E/M) service with modifier -25 to indicate a significant, separately identifiable E/M service was performed on the same day as a procedure. The E/M service entailed:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • An expanded problem-focused history;
  • An expanded problem-focused examination; and
  • A medical decision making of low complexity.

Infliximab is considered a chemotherapy infusion and is reported with CPT code 96413 for the first hour of the infusion; 96415 is used to code each additional hour of the chemotherapy infusion up to eight hours, because the infusion was given for two hours and 10 minutes. Time starts for the infusion when the medication starts to drip, not when the IV port is inserted. Although the diphenhydramine was given to the patient prior to the infusion, coding guidelines indicate that the primary procedure should be billed first, followed by any subsequent code.

The 2006 CMS Transmittal 968 Change Request 5028 on coding revision for “Chemotherapy Administration and Nonchemotherapy Injection and Infusion Coding Policy” indicates:

When administering multiple infusions, injections or combinations, the physician should report only one “initial” service code unless protocol requires that two separate IV sites must be used. The initial code is the code that best describes the key or primary reason for the encounter and should always be reported irrespective of the order in which the infusions or injections occur. If an injection or infusion is of a subsequent or concurrent nature, even if it is the first such service within that group of services, then a subsequent or concurrent code should be reported. For example, the first IV push given subsequent to an initial one-hour infusion is reported using a subsequent IV push code.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

HCPCS code J1745 is reported for the infliximab 10 mg. Because the patient received 200 mg of infliximab, the correct way to code this is J1745x20 (20 x 10 = 200 mg).

Filed Under: Billing/Coding, Practice Management Tagged With: Billing, Coding, infliximab, Medicare, Practice Management, Rheumatoid arthritis, rheumatologistIssue: August 2012

You Might Also Like:
  • Coding Corner Answer: July Coding Challenge
  • Coding Corner Answer: December Coding Challenge
  • Coding Corner Answer
  • Rheumatology Coding Corner Answer: Physical Examination with Infliximab Infusion

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)